Compare Ascendis Pharma A/S (ASND) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Xcel Energy Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Xcel Energy Inc trades at $80.08 (market cap $49.98B). The key difference: Xcel Energy Inc is far larger — about 2.8× Ascendis Pharma A/S's market cap, and Xcel Energy Inc pays a 2.96% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | XEL | |
|---|---|---|
Market Cap | $17.74B | $49.98B |
Sector | Health | Utilities |
52-Week High | $277.18 | $83.91 |
52-Week Low | $163.32 | $68.33 |
Enterprise Value | $18.11B | $87.42B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
XEL trades at $80.06, up 1.32% today, with a bearish technical signal but strong analyst consensus. Recent earnings showed a Q1 2026 beat but two prior misses. The company maintains solid fundamentals with $14.67B revenue, 14.14% net margin, and a $60B capital plan driving growth. Dividend yield is 2.87% with a recent $0.59 payout declared.
Outlook is positive with Wall Street's $91.88 price target suggesting 15% upside, supported by data center demand and infrastructure investments. Risks include regulatory pushback on rate hikes and high debt levels. The stock presents a steady utility play with growth catalysts but requires monitoring of earnings consistency and capex execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
